About Vertex Pharmaceuticals Incorpor
Vertex Pharmaceuticals Incorpor (VRTX) is a Healthcare company in the Pharmaceutical Preparations industry with a market capitalisation of $141.1B. The stock trades at 32.18x trailing earnings.
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Market cap
- $141.1B
- P/E ratio
- 32.18
- EPS (TTM)
- $15.32
- Revenue (TTM)
- $12B
- Free cash flow
- $3.2B
- Profit margin
- 32.9%
- Shares outstanding
- 253.5M
Financial health: Strong9.3/10
6 strengths, 0 concerns. No red flags against these benchmarks.
- Current ratio: 2.90 (Strong, benchmark > 1.5) — Short-term assets cover 2.90x short-term liabilities, against Graham's 1.5x floor. It has deteriorated over the last 4 years.
- Return on equity: 21.2% (Strong, benchmark > 15%) — Earns 21.2% on shareholder equity, comfortably past the > 15% mark.
- Gross margin: 86.0% (Strong, benchmark > 40%) — Keeps 86.0% of revenue after the direct cost of sales, comfortably past the > 40% mark.
- Net margin: 32.9% (Strong, benchmark > 10%) — Turns 32.9% of revenue into profit, comfortably past the > 10% mark.
- Free cash flow: $3.2B (Strong, benchmark positive) — Generated $3.2B of free cash flow after capital spending. It has deteriorated over the last 4 years.
- Revenue growth: 8.9% (Watch, benchmark > 10%) — Revenue changed 8.9% year on year, short of the > 10% mark.
- Earnings growth: 838.1% (Strong, benchmark > 10%) — Earnings changed 838.1% year on year, comfortably past the > 10% mark.